There is an urgent need for clinicians to be able to examine a set of biomarkers such as eIF4E and downstream effector molecules in order to set a current standard for prognosis. Acknowledgements The authors gratefully Apoptosis inhibitor acknowledge the help of Ms. Wanda Green and Dr. Jill Williams in the preparation of the TMAs. The authors also thank the other members of the Breast Cancer Focus Group for helpful discussions on the preparation of this manuscript: Dr. Fleurette Abreo,
Dr. Jun Chung, Dr. Shile Huang, Dr. Kevin Pruitt, Dr. Robert Rhoads, Dr. Amanda Sun, Dr. Songlin Zhang, and Dr. Qian-Jin Zhang. This research was supported by funding from the Feist-Weiller Cancer Center, Shreveport and the Louisiana Gene Therapy Research Consortium. References 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007, 57: 43–66.CrossRefPubMed 2. De Benedetti A, Harris AL: eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999, 31: 59–72.CrossRefPubMed 3. Dillon RL, White DE, Muller WJ: The phosphatidyl inositol
3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26: 1338–1345.CrossRefPubMed 4. Santen Ipatasertib purchase RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80: 239–256.CrossRefPubMed 5. Wu JT, Kral JG: The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg
Res 2005, 123: 158–169.CrossRefPubMed 6. Sonenberg N: Regulation of translation and cell growth by eIF-4E. Biochimie 1994, 76: 839–846.CrossRefPubMed 7. Richter JD, Sonenberg SSR128129E N: Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005, 433: 477–480.CrossRefPubMed 8. https://www.selleckchem.com/products/necrostatin-1.html Shantz LM, Pegg AE: Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994, 54: 2313–2316.PubMed 9. Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS: Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996, 65: 785–790.CrossRefPubMed 10. Zimmer SG, DeBenedetti A, Graff JR: Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000, 20: 1343–1351.PubMed 11. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV: Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993, 13: 7358–7363.PubMed 12.
Related posts:
- Cancer Genet Cytogenet 2003, 140: 145–152 CrossRefPubMed 10 Cher
- Infect Immun 2009,77(6):2447–2454 CrossRefPubMed 26 Zarnowski R,
- Int J Food Microbiol 2010, 141:82–89 CrossRefPubMed 27 Villena J
- Psychol Health 2004, 19: 749–765 CrossRef 10 Schlich-Bakker KJ,
- J Glin Microbiol 2008, 46:470–6 72 Hussain M, Haggar A, Peters